Occidental Petroleum (OXY Quick QuoteOXY - Free Report) is a large cap E&P which also has a chemical business. While it’s considered a more conservative play on the crude rebound because of its size, investors also get solid management and a dividend still yielding 3.7% even though the stock has rebounded off the 2017 lows. This Zacks Rank #1 (Strong Buy) is expected to see earnings jump an incredible 389% in 2018 as crude prices rise.

CRISPR Therapeutics (CRSP Quick QuoteCRSP - Free Report) is a gene editing biotech which is not yet profitable. However, the drug industry sees promise in this technology and is willing to fund R&D in these early stages. Kevin warns the stock isn’t for everyone. He also discusses how biotech investors can do their homework when buying in this industry. He answers the age-old question of “how did CRISPR get a #1 Rank if it has negative earnings?”

Should these two companies be on your investing short list? Find out in this week’s video.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>